Rare Diseases and Orphan Drugs Journal Convenes Second Editorial Board Meeting
On October 23, 2025, Rare Diseases and Orphan Drugs Journal (RDODJ), led by Editor-in-Chief Prof. Daniel Scherman, successfully held its second online Editorial Board meeting. Since its launch in 2021, RDODJ has steadily grown and is now indexed in ESCI, Scopus, Dimensions, and Lens, reflecting its growing international impact.
During the meeting, Prof. Scherman expressed his gratitude to the editorial team for their dedication and reaffirmed the journal's commitment to publishing high-quality, rigorous research. The board outlined an ambitious goal for RDODJ: to achieve a Q2 ranking in the next official evaluation, further enhancing its global scientific influence.
The discussions focused on strategies to optimize the editorial process. Key initiatives include the formation of a new pre-check team for initial manuscript assessments and measures to ensure rigorous standards in peer review. These efforts support RDODJ's vision of becoming a leading platform for research on rare diseases and orphan drugs, encouraging high-quality contributions from both established and emerging researchers worldwide.
Attendees
| Position | Name | Institution |
|---|---|---|
| Editor-in-Chief | Daniel Scherman | Laboratory of Chemical and Biological Technology for Health, Faculty of Pharmacy, Paris University, Paris, France; Fondation Maladies Rares - Foundation for Rare Diseases, Paris, France |
| Associate Editors | Jacques S. Beckmann | Faculty of Biology and Medicine, University of Lausanne, Lausanne, Switzerland |
| Tao Duan | Clinical and Translational Research Center & Department of Obstetrics, Shanghai First Maternity and Infant Hospital, Tongji University School of Medicine, Shanghai, China | |
| Phillip D. K. Lee | University of Texas Medical Branch, Galveston, TX, USA | |
| Joe N. Kornegay | Departments of Veterinary Integrative Biosciences and Veterinary Pathobiology, College of Veterinary Medicine & Biomedical Sciences, Texas A&M University, College Station, TX, USA | |
| Editorial Board Members | David Pearce | Department of Pediatrics, Sanford School of Medicine, University of South Dakota, Sioux Falls, SD, USA |
| Jinxiang Han | Biomedical Sciences College & Shandong Medicinal Biotechnology Centre, Shandong First Medical University & Shandong Academy of Medical Sciences, Jinan, Shandong, China | |
| Xiaoping Luo | Tongji Children's Hospital; Department of Pediatrics, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China | |
| Manuel Posada de la Paz | Institute of Rare Diseases Research (IIER), Instituto de Salud Carlos III, Madrid, Spain | |
| Ke Wu | Department of Gastrointestinal Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China | |
| Rodrigue Rossignol | INSERM U1211 Rare Diseases, Genetics and Metabolism, University of Bordeaux, Bordeaux, France | |
| Reena Kartha | Center for Orphan Drug Research, University of Minnesota, MN, USA | |
| Virginie Hivert | EURORDIS-Rare Diseases Europe, Paris, France | |
| Daniel O'Connor | Medicines and Healthcare Products Regulatory Agency, Canary Wharf, London, UK | |
| Junior Editorial Board Members | Lluis Samaranch | Department of Neurological Surgery, College of Medicine, The Ohio State University Wexner Medical Center, Columbus, OH, USA |
Editor: Monica
Language Editor: Catherine Yang
Production Editor: Ting Xu
Respectfully submitted by the Editorial Office of Rare Disease and Orphan Drugs Journal
